Evaluation of 68Ga-DOTATOC PET/CT-enterography for detecting primary lesions in small bowel neuroendocrine tumors

What this Trial Is About

Neuroendocrine tumors of the small intestine (Si-NENs) are rare cancers where surgery is the only cure for early stages, but its use in advanced metastatic cases is debated. Accurate detection of tumor spread and grading is key for prognosis and treatment decisions. This research focuses on improving detection methods using advanced imaging to better identify primary tumors and multifocal disease in the small bowel. Participants will undergo PET/CT-enterography using 68Ga-DOTATOC, a specialized imaging technique that targets somatostatin receptors commonly found on neuroendocrine tumors. This method aims to provide detailed and precise imaging that may be superior to conventional scans. The study will assess how well this imaging detects the primary tumor and multifocal lesions in patients with small bowel neuroendocrine tumors. During the study, researchers will evaluate the sensitivity, specificity, positive and negative predictive values, and overall accuracy of the 68Ga-DOTATOC PET/CT-enterography over a three-month period. Participants eligible for surgery with any tumor grade will be included. This imaging study helps doctors better determine disease burden, which is essential for planning the best treatment approach.

Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel